Tibet Aim Pharm Inc (002826) - Total Assets
Based on the latest financial reports, Tibet Aim Pharm Inc (002826) holds total assets worth CN¥1.06 Billion CNY (≈ $154.93 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Tibet Aim Pharm Inc for net asset value and shareholders' equity analysis.
Tibet Aim Pharm Inc - Total Assets Trend (2013–2024)
This chart illustrates how Tibet Aim Pharm Inc's total assets have evolved over time, based on quarterly financial data.
Tibet Aim Pharm Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tibet Aim Pharm Inc's total assets of CN¥1.06 Billion consist of 57.0% current assets and 43.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 46.1% |
| Accounts Receivable | CN¥55.34 Million | 6.0% |
| Inventory | CN¥41.05 Million | 4.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥20.70 Million | 2.2% |
| Goodwill | CN¥16.67 Million | 1.8% |
Asset Composition Trend (2013–2024)
This chart illustrates how Tibet Aim Pharm Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tibet Aim Pharm Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tibet Aim Pharm Inc's current assets represent 57.0% of total assets in 2024, an increase from 51.0% in 2013.
- Cash Position: Cash and equivalents constituted 46.1% of total assets in 2024, up from 17.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 14.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.0% of total assets.
Tibet Aim Pharm Inc Competitors by Total Assets
Key competitors of Tibet Aim Pharm Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Tibet Aim Pharm Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.67 | 2.51 | 2.06 |
| Quick Ratio | 2.52 | 2.32 | 1.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥420.82 Million | CN¥315.92 Million | CN¥231.98 Million |
Tibet Aim Pharm Inc - Advanced Valuation Insights
This section examines the relationship between Tibet Aim Pharm Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.29 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | -0.1% |
| Total Assets | CN¥926.47 Million |
| Market Capitalization | $544.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tibet Aim Pharm Inc's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Tibet Aim Pharm Inc's assets decreased by 0.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Tibet Aim Pharm Inc (2013–2024)
The table below shows the annual total assets of Tibet Aim Pharm Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥926.47 Million ≈ $135.57 Million |
-0.14% |
| 2023-12-31 | CN¥927.74 Million ≈ $135.76 Million |
-8.88% |
| 2022-12-31 | CN¥1.02 Billion ≈ $149.00 Million |
+23.50% |
| 2021-12-31 | CN¥824.47 Million ≈ $120.65 Million |
-9.21% |
| 2020-12-31 | CN¥908.09 Million ≈ $132.88 Million |
+8.70% |
| 2019-12-31 | CN¥835.41 Million ≈ $122.25 Million |
+10.22% |
| 2018-12-31 | CN¥757.93 Million ≈ $110.91 Million |
+3.36% |
| 2017-12-31 | CN¥733.29 Million ≈ $107.30 Million |
+13.45% |
| 2016-12-31 | CN¥646.36 Million ≈ $94.58 Million |
+62.53% |
| 2015-12-31 | CN¥397.70 Million ≈ $58.20 Million |
+48.16% |
| 2014-12-31 | CN¥268.42 Million ≈ $39.28 Million |
+75.32% |
| 2013-12-31 | CN¥153.10 Million ≈ $22.40 Million |
-- |
About Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcoh… Read more